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Abstract
 
Benign familial hematuria (BFH) is characterized by auto-
somal dominant inheritance, thinning of the glomerular
basement membrane (GBM) and normal renal function. It
is frequent in patients with persistent microscopic hema-
turia, but cannot be clinically differentiated from the initial
stages of Alport syndrome, a severe GBM disorder which
progresses to renal failure. We present here linkage of be-
nign familial hematuria with the 
 
COL4A3
 
 and 
 
COL4A4
 
genes at 2q35-37 (Z
 
max
 
 
 
5
 
 3.58 at 
 
U 5
 
 0.0). Subsequently, a
glycine to glutamic acid substitution was identified in the
collagenous region of the 
 
COL4A4
 
 gene. We conclude that
type IV collagen defects cause both benign hematuria and
Alport syndrome. Furthermore, our data suggest that BFH
patients can be carriers of autosomal recessive Alport syn-
drome. (
 
J. Clin. Invest. 
 
1996. 98:1114–1118.) Key words: he-
maturia 
 
•
 
 Alport syndrome 
 
•
 
 basement membrane 
 
•
 
 collagen
 
•
 
 mutation analysis
 
Introduction
 
Hematuria is the presenting symptom in a large number of re-
nal disorders. If the hematuria occurs in childhood, is isolated
and is of glomerular origin, the diagnosis is difficult to reach.
Benign hematuria, Alport syndrome and IgA-nephropathy all
present with persistent hematuria. Particularly, differentiation
between Alport syndrome, which is a severe renal disorder,
progressing to renal failure in most cases, and benign hema-
turia is mandatory for correct prediction of prognosis and ge-
netic counseling. In benign hematuria electron microscopic
analysis of renal biopsies shows thinning of the glomerular
basement membrane (GBM)
 
1
 
 (1–3), while in Alport syndrome
renal biopsies are characterized by irregular thickening and
multilamination of the GBM (4). However, thinning of the
GBM may be the only microscopic abnormality in younger
Alport patients (5–7), which hampers the differentiation be-
tween the two disorders in childhood. Renal biopsies of 65
children with isolated hematuria persisting for at least one year
revealed histological abnormalities consistent with Alport syn-
drome in eight cases and consistent with benign hematuria in
33 cases (3). A positive family history was detected in 23 of the
33 cases.
The major structural component of the GBM is formed by
a type IV collagen network. As yet, six different type IV col-
lagen chains have been identified and the respective genes
were cloned. Mutations were detected in three type IV col-
lagen genes in Alport syndrome. The majority was present in
the X-linked type IV collagen 
 
a
 
5 (
 
COL4A5
 
) gene, but re-
cently mutations in the type IV collagen 
 
a
 
3 and 
 
a
 
4 (
 
COL4A3/
A4
 
) genes have been reported in patients with the autosomal
recessive form of this disease (8, 9). These latter two collagen
genes are localized head to head on the tip of the long arm of
chromosome 2 (10). Considering the similarities in GBM ab-
normalities, autosomal Alport syndrome and BFH could be
the severe and mild forms of different molecular genetic de-
fects in the same genes. Here we report linkage of the
 
COL4A3/A4
 
 locus to BFH in a large Dutch family (11) and
the identification of a pathogenic mutation in the 
 
COL4A4
 
gene.
 
Methods
 
Patients. 
 
The index patient (III:10; see Fig. 1) presented with hema-
turia at the age of 5 years. There were no concomitant abnormalities,
i.e., glomerular filtration rate was normal and hypercalciuria was ab-
sent. There was also no hypertension. The morphology of the eryth-
rocytes in the urinary sediment indicated a glomerular origin of the
cells. Audiography and fundoscopy revealed no abnormalities. Fam-
ily history was negative for renal failure and deafness. One year later
a renal biopsy was performed. Electron microscopy of the biopsy
specimen showed regions with malformations of the glomerular base-
ment membrane, typical for Alport syndrome, and regions which
were thin. Further investigation of the family showed microscopic he-
maturia in both parents and his younger brother (III:11), but no other
symptoms suggestive for Alport syndrome. Renal function was nor-
mal in the parents (II:7 and II:8; normal serum creatinine concentra-
tion). Microscopic hematuria was present in three sisters of the father
(II:7) and in half of their off-spring, as well as in the grandfather (I:1;
Fig. 1). Particularly important is that this 75-yr-old man had a normal
serum creatinine concentration. In the family of the mother (II:8) he-
maturia was also widely present. Her 76-yr-old father had hematuria
and a normal creatinine level, her mother was healthy. It was con-
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Abbreviations used in this paper:
 
 BFH, benign familial hematuria;
GBM, glomerular basement membrane.
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cluded that the family history on both sides strongly supported the di-
agnosis BFH. The index patient might have inherited the disorder
form both parents, which could explain the aberrant morphology of
the biopsy specimen. He is presently 16 years old and symptoms are
hematuria and recently developed proteinuria (0.5 grams/liter). He-
maturia was defined as a condition with 10 or more erythrocytes per
mm
 
3
 
 urine, established by the quantitative sediment method of Gade-
holt (12). Individuals with borderline values were repeatedly ana-
lyzed. All family members could unambiguously be scored as either
affected or unaffected.
 
Linkage analysis. 
 
Blood samples were collected from family
members and genomic DNA was isolated by a salting out procedure
(13). The 
 
COL4A3/COL4A4
 
 CA repeat was PCR amplified using
125 ng of primers CA11F (5
 
9
 
-ATC TCT CAG GGT GCG TGC-3
 
9
 
)
and CA11R (5
 
9
 
-CTC ATT GAT ACA CAC AAA TGC A-3
 
9
 
) and
50-100 ng DNA template in a standard Cetus buffer with 2 mM
MgCl
 
2
 
. After 3 min at 94
 
8
 
C, four initial cycles were performed of 1 min
at 94
 
8
 
C, 1 min at 58
 
8
 
C and 1 min at 72
 
8
 
C followed by 30 cycles of 1
min at 94
 
8
 
C, 1 min at 55
 
8
 
C and 1 min at 72
 
8
 
C. One of the primers was
fluorescently labeled and the PCR product was analyzed on an ABI
373A Automated Sequencer using the Genescan software package
(Applied Biosystems, Foster City, CA). A 
 
COL4A4
 
 HaeIII RFLP
was identified by SSCP and subsequent sequence analysis and is
caused by a neutral mutation at the 1198glycine residue of the
 
COL4A4
 
 gene. PCR was performed on 100 ng genomic DNA using
100 ng of intronic oligonucleotides A4IF10 (5
 
9
 
-AGGCACTATAAC-
AGGGACAAGA-3
 
9
 
) (9) and 714 (5
 
9
 
-CCTCATTGCATTTGGAAG-
GT-3
 
9
 
), 200 
 
m
 
M dNTPs, 5% DMSO in Ampli-Taq buffer containing
67 mM Tris-HCl (pH 
 
5
 
 8.8), 16.6 mM (NH
 
2
 
)SO
 
4
 
, 6.7 mM MgCl
 
2
 
, 0.17
mg/ml BSA (Boehringer Mannheim, Germany) to a total volume of
25 
 
m
 
l. The sequence of oligo 714 is the reverse of oligonucleotide
A4IF9 (9). After 5 min of denaturation at 96
 
8
 
C 1 U Ampli-Taq DNA
polymerase (Perkin-Elmer, Norwalk, CT) was added and 30 cycles of
PCR were started (denaturation at 94
 
8
 
C for 1 min, annealing at 62
 
8
 
C
for 1 min and extension at 72
 
8
 
C for 1 min and 30 s). If the HaeIII site
is present, digestion of the PCR fragment (260 bp) gives two bands of
182 and 78 bp (data not shown).
Two point and multi-point lod scores were calculated using the
MLINK and LINKMAP options of the LINKAGE package com-
puter program (version 5.03) (14). BFH was defined as an autosomal
dominant disorder with complete penetrance. The disease frequency
was estimated to be 0.0001.
 
Mutation analysis. 
 
RNA was isolated from peripheral blood
lymphocytes (PBL) or EBV transformed PBL from affected and nor-
mal individuals by RNAzol extraction (15). 
 
COL4A3
 
 and 
 
COL4A4
 
cDNA fragments were generated by RT-PCR analysis as described
before (8, 16). Oligonucleotides were designed to amplify 
 
COL4A3
 
and 
 
COL4A4
 
 cDNA by multiple overlapping cDNA fragments.
DNA fragments were sequenced on an ABI 373A automated se-
quencer. Reaction conditions using dyedeoxy
 
TM
 
-terminators were ac-
cording to a protocol provided by the manufacturer (Applied Biosys-
tems, Foster City, CA). The Gly897Glu mutation was identified in
the PCR fragment, flanked by outer primers 945 (5
 
9
 
-GCGAAG-
GGTGACATGGTTGTATCA-3
 
9
 
) starting at position 1871 and 946
(5
 
9
 
-CCTCTCAGAAGGTCAACACTCCCAG-3
 
9
 
) starting at position
4074 (17) in a first round of 35 cycles; denaturation for 1 min at 92
 
8
 
C,
1 min 30 s of annealing at 60
 
8
 
C and extension for 3 min at 72
 
8
 
C. Two
microliters out of the first PCR reaction was used as template for a
second round of 35 cycles using inner primers F100 (5
 
9
 
-AAGGCC-
TCCCCGGACTCCCA-3
 
9
 
) at position 2750 and R101 (5
 
9
 
-CGGGAG-
GTCCTATGGCTC-3
 
9
 
) at position 3017 (17); denaturation for 1 min
at 92
 
8
 
C, 1 min 30 s of annealing at 55
 
8
 
C and extension for 2 min at
72
 
8
 
C. The Gly897Glu mutation created an AluI restriction site and
was screened at the genomic DNA level by PCR amplification using
oligonucleotides F100 (5
 
9
 
-AAGGCCTCCCCGGACTCCCA-3
 
9
 
) and
1106 (5
 
9
 
-ACCTGGAGGACCAGGTAGC-3
 
9
 
) and digestion with
AluI restriction enzyme (GIBCO BRL, Gaithersburg, MD). If the
mutation is present the 104-bp PCR fragment is cleaved in two frag-
ments of 86 and 18 bp. The smallest fragment is not visible.
 
Results
 
Linkage analysis. 
 
Linkage analysis was performed with two
novel polymorphic markers from the 
 
COL4A3/COL4A4
 
 lo-
cus. The most informative marker was a CA repeat, isolated
from a YAC clone with an insert of 540 kb, containing both
 
COL4A3
 
 and 
 
COL4A4
 
 genes (18). The other marker was a
Figure 1. Segregation analysis of type IV collagen a3 and a4 markers in the BFH family. Haplotypes were constructed for the type IV collagen 
a3/a4 CA repeat and the type IV collagen a4 HaeIII RFLP. Type IV collagen a3/a4 CA repeat fragments are indicated as the length of the PCR 
fragment in basepairs (76, 78, and 80 bp). The HaeIII RFLP alleles are represented by 1 (HaeIII site absent) and 2 (HaeIII site present). The 
haplotype [78, 2], shown as black bars, cosegregates with BFH. Filled symbols indicate individuals with hematuria. Arrow indicates index patient 
(III-10).
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HaeIII RFLP in one of the exons of the 
 
COL4A4 
 
gene. Be-
cause the genomic structure of
 
 COL4A4
 
 is not clarified yet,
the exact numbering of exons is unknown, but most likely exon
8 is involved (counting from the 3
 
9
 
 end). The RFLP is caused
by a polymorphism, a neutral G to A nucleotide substitution at
Glycine1198 (GGG into GGA) (17). The allele frequencies of
this polymorphism were 0.5/0.5 (70 unrelated individuals
tested).
Figure 2. Gly897Glu substitu-
tion in the type IV collagen a4 
chain in BFH. Sequence analysis 
of type IV collagen a4 cDNA of 
the index patient and a normal 
control. The mutation, which 
changes the glycine (G) codon 
897 GGG into the glutamic acid 
(E) codon GAG is indicated by 
an arrow. Type IV collagen 
chains consist of collagenous 
and non-collagenous (NC) do-
mains. Three type IV collagen 
chains form a triple helix, which 
is interrupted by the substitution 
of a conserved glycine residue.
Figure 3. Segregation of Gly897Glu 
mutation in the BFH family. The 
presence of the mutation creates an 
additional AluI restriction site. 
Cleavage of the 104 bp PCR frag-
ment in two shorter fragments of 86 
and 18 basepairs is indicative for the 
presence of the mutation. Only the 
affected family members (filled sym-
bols) show the shorter DNA frag-
ment (86 bp), the smallest fragment 
of 18 bp is not visible. DNA fragment 
lengths are indicated in basepairs 
(bp).
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Linkage analysis was performed in the paternal (II:7) side
of the pedigree (Fig. 1). The mother (II:8) and her two sons,
III:10 and III:11 (Fig. 1), were not included in the linkage stud-
ies, because BFH segregated also in the maternal line. The
maternal relatives were not available for linkage analysis. A
maximum lod score (
 
Z
 
max
 
) of 3.01 was obtained in the paternal
(II:7; Fig. 1) line with the 
 
COL4A3/COL4A4
 
 CA repeat at re-
combination fraction (
 
U
 
) of 0.0 in our family. The 
 
Z
 
max
 
 ob-
tained with the intragenic 
 
COL4A4
 
 RFLP is 1.51 at 
 
U
 
 
 
5
 
 0.0.
All affected individuals share the haplotype [78, 2] for both
markers (Fig. 1). This haplotype was linked to BFH with a
 
Z
 
max
 
 of 3.58 at 
 
U
 
 
 
5
 
 0.0.
 
Mutation analysis. 
 
RT-PCR was performed on total lym-
phocyte RNA followed by direct sequence analysis of ampli-
fied 
 
COL4A3
 
 and COL4A4 cDNA fragments. A heterozy-
gous G to A nucleotide substitution was identified at position
2898 of the COL4A4 gene in the patients III:10 and III:11 and
in their father II:7, but not in their mother II:8. The glycine
codon GGG at position 897 was changed into GAG, encoding
a glutamic acid residue (Fig. 2). The mutation introduced a
novel site for the restriction enzyme AluI and the other family
members and controls were screened for the presence of this
site. If the AluI site is present, a 104 bp PCR fragment will be
cleaved in two smaller fragments of 86 and 18 bp (Fig. 2). All
affected family members were heterozygous for the mutation
(Fig. 3) and the mutation was not detected in the unaffected
family members and 50 unrelated controls (data not shown).
Discussion
For several reasons, the Gly897Glu mutation in the type IV
collagen a4 chain is likely to be the pathogenic mutation in the
BFH family. First, the mutation changes a glycine in a con-
served collagenous triple helical domain in the type IV col-
lagen a4 chain (17). Every third amino acid is a glycine, be-
cause it is the only residue small enough to fit into the center of
the triple helical molecule (19). If glycine residues are substi-
tuted by bulkier amino acids such as glutamic acid the triple
helix structure will be distorted (Fig. 2). Unlike fibrillar col-
lagens, type IV collagen triple helices contain 21–26 interrup-
tions, which are assumed to provide flexibility to the molecule.
However, the positions of these interruptions are highly con-
served during evolution and the generation of an additional in-
terruption may interfere with correct folding of the intricate
type IV collagen trimers, consisting of type IV collagen a3, a4,
and a5 chains. Substitutions for glycines in the collagenous tri-
ple helical domain are also a common cause of other collagen
disorders, like osteogenesis imperfecta and Ehlers Danlos syn-
drome (20). Furthermore, the mutation cosegregates with
BFH in our family and, finally, the mutation is absent from a
control group of 50 individuals, which provides additional evi-
dence for the pathogenicity of the defect.
In 1994, homozygous mutations in the type IV collagen a3
and a4 genes have been identified in patients with autosomal
recessive Alport syndrome (8, 9). Two different mutations
were reported in the type IV collagen a4 gene: a glycine to
serine substitution and a serine to stop mutation (9). Similar to
the Gly897Glu mutation in the BFH family presented here,
the glycine is substituted in the triple helical domain of the
type IV collagen a4 chain. Our data suggest that BFH patients
can be manifesting carriers of autosomal recessive Alport syn-
drome. This is in line with the histological examination of the
kidney biopsy and the presence of proteinuria in the index pa-
tient, who is a suspected compound BFH heterozygote. The
definite proof awaits the detection of the second maternal
BFH mutation and the progression of his renal disease.
In conclusion, this is the first report on a genetic defect ex-
plaining benign hematuria. The identification of type IV col-
lagen defects, similar to those found in Alport syndrome, is im-
portant for genetic counseling and prognostic prediction. As
yet, this prediction can not be based on the mutation only, but
needs a complete investigation of family history, follow-up ex-
amination and renal biopsy. In a recent report linkage of the
rare autosomal dominant form of Alport syndrome to the type
IV collagen a3 and a4 locus was demonstrated in a large
Northern-Irish family (Jefferson, J.A., A.P. Maxwell, A.E.
Hughes, C.M. Hill, C.C. Doherty, and N.C. Nevin. Autosomal
dominant Alport syndrome linked to the type IV collagen a3
and a4 genes (COL4A3 and COL4A4), manuscript submitted
for publication). It is obvious that the type IV collagen a3 and
a4 genes are strong candidates for the autosomal dominant
form of Alport syndrome as well. This would complete the
spectrum of phenotypes of type IV collagen a3 and a4 defects,
ranging from neutral amino acid substitutions (8) and benign
hematuria to mild autosomal dominant and severe recessive
Alport syndrome. In this way, the type IV collagen mutations
fit within the rule of extreme clinical and genetic variability of
collagen disorders (21).
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